192 related articles for article (PubMed ID: 33498757)
1. Targeted Metabolomics Identifies Plasma Biomarkers in Mice with Metabolically Heterogeneous Melanoma Xenografts.
Weber DD; Thapa M; Aminzadeh-Gohari S; Redtenbacher AS; Catalano L; Feichtinger RG; Koelblinger P; Dallmann G; Emberger M; Kofler B; Lang R
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33498757
[TBL] [Abstract][Full Text] [Related]
2. Ketogenic diets slow melanoma growth in vivo regardless of tumor genetics and metabolic plasticity.
Weber DD; Aminzadeh-Gohari S; Thapa M; Redtenbacher AS; Catalano L; Capelôa T; Vazeille T; Emberger M; Felder TK; Feichtinger RG; Koelblinger P; Dallmann G; Sonveaux P; Lang R; Kofler B
Cancer Metab; 2022 Jul; 10(1):12. PubMed ID: 35851093
[TBL] [Abstract][Full Text] [Related]
3. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI; Widmer DS; Narechania A; Eichhoff O; Freiberger SN; Wenzina J; Cheng PF; Mihic-Probst D; Desalle R; Dummer R; Levesque MP
Oncotarget; 2016 Nov; 7(47):77163-77174. PubMed ID: 27791198
[TBL] [Abstract][Full Text] [Related]
4. Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity.
Kaji T; Yamasaki O; Takata M; Otsuka M; Hamada T; Morizane S; Asagoe K; Yanai H; Hirai Y; Umemura H; Iwatsuki K
J Dermatol Sci; 2017 Jan; 85(1):51-57. PubMed ID: 27771229
[TBL] [Abstract][Full Text] [Related]
5. Targeted Genomic Profiling of Acral Melanoma.
Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
[TBL] [Abstract][Full Text] [Related]
6. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
7. Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma.
Krebs FS; Moura B; Missiaglia E; Aedo-Lopez V; Michielin O; Tsantoulis P; Bisig B; Trimech M; Zoete V; Homicsko K
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901951
[TBL] [Abstract][Full Text] [Related]
8. Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma.
Doma V; Kárpáti S; Rásó E; Barbai T; Tímár J
BMC Cancer; 2019 Aug; 19(1):786. PubMed ID: 31391014
[TBL] [Abstract][Full Text] [Related]
9. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
Saldanha G; Potter L; Daforno P; Pringle JH
Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
[TBL] [Abstract][Full Text] [Related]
11. Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAF
Jandova J; Park SL; Corenblum MJ; Madhavan L; Snell JA; Rounds L; Wondrak GT
Mol Carcinog; 2022 Jun; 61(6):603-614. PubMed ID: 35417045
[TBL] [Abstract][Full Text] [Related]
12. The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma.
Guhan SM; Shaughnessy M; Rajadurai A; Taylor M; Kumar R; Ji Z; Rashid S; Flaherty K; Tsao H
J Invest Dermatol; 2021 Aug; 141(8):2018-2027.e4. PubMed ID: 33745909
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Targeted Radionuclide Therapy Using [
Akil H; Quintana M; Raymond JH; Billoux T; Benboubker V; Besse S; Auzeloux P; Delmas V; Petit V; Larue L; D'Incan M; Degoul F; Rouanet J
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804655
[TBL] [Abstract][Full Text] [Related]
14. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
15. NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma.
Li H; Zhang Q; Duan Q; Tan Y; Sun T; Qi C
Front Immunol; 2022; 13():894110. PubMed ID: 35967450
[TBL] [Abstract][Full Text] [Related]
16. Atypical
Dumaz N; Jouenne F; Delyon J; Mourah S; Bensussan A; Lebbé C
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31398831
[TBL] [Abstract][Full Text] [Related]
17. Belvarafenib penetrates the BBB and shows potent antitumor activity in a murine melanoma brain metastasis model.
Kim YY; Park H; Song T; Choi K; Dolton M; Mao J; Kim J; Ahn YG; Suh KH; Kim YH
Clin Exp Metastasis; 2023 Apr; 40(2):137-148. PubMed ID: 36763292
[TBL] [Abstract][Full Text] [Related]
18.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
19. Mutational Landscape and Outcomes of Conjunctival Melanoma in 101 Patients.
Lally SE; Milman T; Orloff M; Dalvin LA; Eberhart CG; Heaphy CM; Rodriguez FJ; Lin CC; Dockery PW; Shields JA; Shields CL
Ophthalmology; 2022 Jun; 129(6):679-693. PubMed ID: 35085662
[TBL] [Abstract][Full Text] [Related]
20. Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions.
Lee SH; Kim JE; Jang HS; Park KH; Oh BH; Shin SJ; Chung KY; Roh MR; Rha SY
Cancer Res Treat; 2018 Oct; 50(4):1378-1387. PubMed ID: 29361821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]